|
|
|
|
Bermuda
|
|
001-37418
|
|
98-1333697
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
Suite 1, 3rd Floor
11-12 St. James’s Square
London SW1Y 4LB, United Kingdom
(Address of principal executive offices) (Zip Code)
|
|
¨
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each Class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Shares, $0.00001 par value per share
|
|
AXGT
|
|
The Nasdaq Stock Market LLC
|
Name
|
|
Votes For
|
|
Votes Against
|
|
Abstain
|
|
Broker Non-Votes
|
Frank Torti, M.D.
|
|
14,500,114
|
|
478,183
|
|
24,409
|
|
6,093,894
|
Atul Pande, M.D.
|
|
14,854,014
|
|
122,752
|
|
25,940
|
|
6,093,894
|
George Bickerstaff
|
|
14,839,396
|
|
139,316
|
|
23,994
|
|
6,093,894
|
Pavan Cheruvu, M.D.
|
|
14,504,384
|
|
474,452
|
|
23,870
|
|
6,093,894
|
Berndt Modig
|
|
14,835,758
|
|
141,008
|
|
25,940
|
|
6,093,894
|
Ilan Oren
|
|
14,473,652
|
|
503,262
|
|
25,792
|
|
6,093,894
|
Myrtle Potter
|
|
14,535,225
|
|
443,067
|
|
24,414
|
|
6,093,894
|
Senthil Sundaram
|
|
14,832,971
|
|
144,804
|
|
24,931
|
|
6,093,894
|
Votes For
|
|
Votes Against
|
|
Abstain
|
20,842,655
|
|
212,938
|
|
41,007
|
|
|
|
AXOVANT GENE THERAPIES LTD.
|
|
|
|
|
|
|
|
|
Dated:
|
August 16, 2019
|
|
|
|
|
|
|
|
By:
|
/s/ David Nassif
|
|
|
|
|
Name:
|
David Nassif
|
|
|
|
|
Title:
|
Principal Financial Officer and Principal Accounting Officer
|
|